Company Short-Term Debts: Shuttle Pharmaceuticals Holdings (SHPH)

Shuttle Pharmaceuticals develops agents to enhance radiation effects in oncology while minimizing systemic toxicity. The business is protected by patents, meaning risks are limited solely to new scientific discoveries. The share price history on GURU.Markets shows a metric of 0.00, while the company's stability relies on the success of medical trials, as current operating income remains volatile.

This indicator aggregates all liabilities with a maturity of up to one year, reflecting current liquidity and the cost of servicing borrowed capital. An analysis of the short-term debt balance allows for an assessment of the financial stability of Shuttle Pharmaceuticals (SHPH), whose clinical trial outsourcing model—while maintaining full ownership of intellectual property—minimizes capital expenditures, making the borrowing trajectory more predictable.